Paper · 36200072
Interactions of marine sulfated glycans with antithrombin and platelet factor 4.
Zhang W and 4 others. Front Mol Biosci, 2022. Cited by 9 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Interactions of marine sulfated glycans with antithrombin and platelet factor 4. Papers, record 36200072. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36200072
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P20 GM130460 | NIGMS NIH HHS | United States | P20GM130460 | PubMed and NIH | NIH RePORTER |
| R03 NS110996 | NINDS NIH HHS | United States | R03NS110996 | PubMed and NIH | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7,053,378 | Heparin with two binding sites for antithrombin or platelet factor 4. | J Biol Chem | 1982 | https://conductscience.org/library/papers/7053378 | PubMed |
| 2 | 31,374,852 | Galactosaminoglycans: Medical Applications and Drawbacks. | Molecules | 2019 | https://conductscience.org/library/papers/31374852 | PubMed |
| 3 | 28,452,441 | Mechanism and Clinical Presentation of Heparin-Induced Thrombocytopenia. | Hemodial Int | 2001 | https://conductscience.org/library/papers/28452441 | PubMed |
| 4 | 24,838,988 | Anticoagulant motifs of marine sulfated glycans. | Glycoconj J | 2014 | https://conductscience.org/library/papers/24838988 | PubMed |
| 5 | 28,716,753 | The structure-activity relationship between polysaccharides from Sargassum thunbergii and anti-tumor activity. | Int J Biol Macromol | 2017 | https://conductscience.org/library/papers/28716753 | PubMed |
| 6 | 32,919,573 | Inhibition of glucuronomannan hexamer on the proliferation of lung cancer through binding with immunoglobulin G. | Carbohydr Polym | 2020 | https://conductscience.org/library/papers/32919573 | PubMed |
| 7 | 31,527,407 | Comparison of the Interactions of Different Growth Factors and Glycosaminoglycans. | Molecules | 2019 | https://conductscience.org/library/papers/31527407 | PubMed |
| 8 | 31,705,871 | Evaluating Heparin Products for Heparin-Induced Thrombocytopenia Using Surface Plasmon Resonance. | J Pharm Sci | 2020 | https://conductscience.org/library/papers/31705871 | PubMed |
| 9 | 19,883,681 | Potential antioxidant and anticoagulant capacity of low molecular weight fucoidan fractions extracted from Laminaria japonica. | Int J Biol Macromol | 2010 | https://conductscience.org/library/papers/19883681 | PubMed |
| 10 | 26,690,451 | Marine Non-Glycosaminoglycan Sulfated Glycans as Potential Pharmaceuticals. | Pharmaceuticals (Basel) | 2015 | https://conductscience.org/library/papers/26690451 | PubMed |
1 to 10 of 37
See all 37 referencesCited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,946,916 | Heparin microarray-based specific interaction assay of marine sulfated polysaccharides with antithrombin Ⅲ. | Commun Chem | 2026 | https://conductscience.org/library/papers/41946916 | PubMed |
| 41,744,690 | Probing Glycosaminoglycan-Protein Interactions: Applications of Surface Plasmon Resonance. | Biosensors (Basel) | 2026 | https://conductscience.org/library/papers/41744690 | PubMed |
| 41,735,426 | Binding properties of marine sulfated glycans to coagulation (co)-factors using surface plasmon resonance spectroscopy. | Sci Rep | 2026 | https://conductscience.org/library/papers/41735426 | PubMed |
| 41,658,173 | The Antithrombotic Potential of Sulfated-Polysaccharides from Red Seaweed Hypnea musciformis (Wulfen) J.V. Lamouroux: An In Vitro, In Silico and In Vivo Study. | ACS Omega | 2026 | https://conductscience.org/library/papers/41658173 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| PF4 | 5,196 | PubTator's text mining | https://conductscience.org/library/genes/5196 | NCBI Gene |
| SERPINC1 | 462 | PubTator's text mining | https://conductscience.org/library/genes/462 | NCBI Gene |
| TFPI | 7,035 | PubTator's text mining | https://conductscience.org/library/genes/7035 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36200072
GET https://conductscience.org/api/papers/v1/36200072/references?page=2